Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2026 08:28 ET | Source: NurExone Biologic Inc

NurExone Announces Corporate Updates

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
March 04, 2026 08:00 ET | Source: Informed Consent Action Network

ICAN Poll: Overwhelming Majority of Respondents Oppose Glyphosate Stockpiling, Reject Manufacturer Immunity

ICAN poll of 2,569 respondents shows strong opposition to federal glyphosate stockpiling and legal immunity for manufacturers amid safety concerns.
January 08, 2026 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)

Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United StatesTherapy granted United States Food and Drug...
December 09, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan

Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation supports development of innovative investigational gene...
October 21, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure

Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate safety and preliminary efficacy in participants...
October 10, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9

Research Triangle Park, N.C., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle...
October 02, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting

Research Triangle Park, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) --One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the...
September 22, 2025 06:00 ET | Source: AskBio Inc. (AskBio)

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease

Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment...
September 17, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy...
September 16, 2025 17:17 ET | Source: D S Simon

Expert with Bayer Discusses the U.S. Launch of Aspirina Families with YourUpdateTV

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bayer’s Aspirina, the #1 pain relief option in Mexico* and a leading brand across Latin America, is now available in the United States. Recently, Dr....